PH12014502250A1 - Mycoplasma hyopneumoniae vaccine - Google Patents

Mycoplasma hyopneumoniae vaccine

Info

Publication number
PH12014502250A1
PH12014502250A1 PH12014502250A PH12014502250A PH12014502250A1 PH 12014502250 A1 PH12014502250 A1 PH 12014502250A1 PH 12014502250 A PH12014502250 A PH 12014502250A PH 12014502250 A PH12014502250 A PH 12014502250A PH 12014502250 A1 PH12014502250 A1 PH 12014502250A1
Authority
PH
Philippines
Prior art keywords
mycoplasma hyopneumoniae
hyopneumoniae vaccine
hyo
soluble portion
preparation
Prior art date
Application number
PH12014502250A
Other languages
English (en)
Other versions
PH12014502250B1 (en
Inventor
Jeffrey E Galvin
Gregory P Nitzel
Garrett John Keith
James R Ii Kulawik
Tracy L Ricker
Smutzer Megan Marie
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48087777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014502250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of PH12014502250B1 publication Critical patent/PH12014502250B1/en
Publication of PH12014502250A1 publication Critical patent/PH12014502250A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PH12014502250A 2012-04-04 2014-10-03 Mycoplasma hyopneumoniae vaccine PH12014502250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620165P 2012-04-04 2012-04-04
PCT/US2013/035083 WO2013152081A1 (en) 2012-04-04 2013-04-03 Mycoplasma hyopneumoniae vaccine

Publications (2)

Publication Number Publication Date
PH12014502250B1 PH12014502250B1 (en) 2014-12-15
PH12014502250A1 true PH12014502250A1 (en) 2014-12-15

Family

ID=48087777

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502250A PH12014502250A1 (en) 2012-04-04 2014-10-03 Mycoplasma hyopneumoniae vaccine

Country Status (31)

Country Link
US (5) US9120859B2 (https=)
EP (2) EP2833908B1 (https=)
JP (1) JP6271502B2 (https=)
KR (1) KR101747507B1 (https=)
CN (1) CN104271154B (https=)
AR (1) AR090611A1 (https=)
AU (1) AU2013243535C1 (https=)
BR (1) BR112014024533B1 (https=)
CA (1) CA2869603C (https=)
CL (1) CL2014002674A1 (https=)
CO (1) CO7160026A2 (https=)
CR (1) CR20140436A (https=)
CY (1) CY1124982T1 (https=)
DK (1) DK2833908T3 (https=)
ES (1) ES2905302T3 (https=)
GT (1) GT201400210A (https=)
HR (2) HRP20220175T1 (https=)
HU (1) HUE058321T2 (https=)
LT (1) LT2833908T (https=)
MX (2) MX336504B (https=)
MY (1) MY166792A (https=)
NI (1) NI201400117A (https=)
PH (1) PH12014502250A1 (https=)
PL (1) PL2833908T3 (https=)
PT (1) PT2833908T (https=)
RS (1) RS62881B1 (https=)
RU (1) RU2644254C2 (https=)
SI (1) SI2833908T1 (https=)
TW (1) TWI602575B (https=)
UA (1) UA114502C2 (https=)
WO (1) WO2013152081A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
SG11201505086QA (en) * 2012-12-28 2015-07-30 Boehringer Ingelheim Vetmed Immunogenic composition comprising mycoplasma antigens
PT2938747T (pt) 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN105792841B (zh) * 2013-11-21 2019-07-26 财团法人农业科技研究院 防治霉浆菌感染的组合物
WO2015187947A1 (en) * 2014-06-04 2015-12-10 Izard Ryan Methods and compositions for orally dosing postnatal swine
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
CN104324370B (zh) * 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
RU2018127200A (ru) * 2016-01-07 2020-02-07 Университейт Гент Вакцинные штаммы brachyspira hyodysenteriae
WO2017162727A1 (en) * 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 and prrs virus infection comprising albumin
CN106497850B (zh) * 2016-12-20 2019-10-29 天津瑞普生物技术股份有限公司 一种纯化猪肺炎支原体的方法
EP3558351B1 (en) 2016-12-23 2022-01-26 Intervet International B.V. Combination vaccine for swine
US11744883B2 (en) * 2017-12-22 2023-09-05 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
US20220235313A1 (en) 2019-06-10 2022-07-28 ELANCO US, Inc. Mycoplasma media formulations
WO2021018806A1 (en) * 2019-07-26 2021-02-04 Ceva Sante Animale Igg-depleted porcine serum and the uses thereof
JP7657287B2 (ja) 2020-07-24 2025-04-04 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 組合せブタワクチン
KR20220168102A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168099A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168098A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168101A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168097A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168100A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
CN114134098A (zh) * 2021-12-15 2022-03-04 成都史纪生物制药有限公司 一种猪肺炎支原体的灭活方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
WO1987005738A1 (fr) 1986-03-13 1987-09-24 Zahnradfabrik Friedrichshafen Ag Systeme pour irradier des liquides au moyen de faisceaux radioactifs
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
NZ226811A (en) 1987-11-03 1991-06-25 Syntex Inc Adjuvant emulsion comprising a glycopeptide and non-toxic tetra-polyol or pop-poe block copolymer wherein oily particle size is less than 800am
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
CA2082155C (en) 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
DE69201441T3 (de) 1991-06-06 2008-12-04 Boehringer Ingelheim Vetmedica Gmbh Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
DE601062T1 (de) 1991-08-26 1995-05-18 David Allen Benfield Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas).
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
EP0669971B1 (en) 1991-11-15 2003-03-19 Pfizer Inc. Method of producing gram-negative bacterial vaccines
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
PT759780E (pt) 1994-05-10 2001-01-31 American Home Prod Vacina melhorada de vsrb vivo modificado
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
CA2311759A1 (en) 1997-11-26 1999-06-03 Tsungdas Hsu Recombinant mycoplasma hyopneumoniae vaccine
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
CA2290220C (en) 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
WO2003003941A2 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. One dose vaccination with mycoplasma hyopneumoniae
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EP1546357B1 (en) 2002-06-28 2013-08-07 Iowa State University Research Foundation, Inc. Immunogenic mycoplasma hyopneumoniae polypeptides
US7371395B2 (en) * 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
US8449989B2 (en) 2003-10-17 2013-05-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
KR101347503B1 (ko) * 2005-09-09 2014-01-02 인터벳 인터내셔널 비.브이. Ｐｃｖ-2 백신
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
EP1968630B1 (en) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
PL2007419T3 (pl) 2006-04-10 2012-09-28 Intervet Int Bv Szczepionka przeciwko mykoplazmie i PRRSV
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
UA98812C2 (ru) * 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN102256997A (zh) 2008-10-16 2011-11-23 美国辉瑞有限公司 细环病毒分离株和组合物
PL2569007T3 (pl) 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
HUE028877T2 (en) * 2010-08-27 2017-01-30 Intervet Int Bv Test of biological activity of vaccine formulation
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
UA115053C2 (uk) 2012-03-07 2017-09-11 Сева Санте Анімаль Композиція, що містить антиген і ліпополісахарид у формі масло-в-воді, та спосіб її використання (варіанти)
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CA2872789C (en) * 2012-05-17 2019-09-03 Zoetis Llc Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning

Also Published As

Publication number Publication date
US9120859B2 (en) 2015-09-01
US10206991B2 (en) 2019-02-19
WO2013152081A1 (en) 2013-10-10
DK2833908T3 (da) 2022-02-07
US9650600B2 (en) 2017-05-16
EP2833908B1 (en) 2022-01-05
HRP20140957A2 (hr) 2015-02-27
US10668139B2 (en) 2020-06-02
RU2644254C2 (ru) 2018-02-08
CY1124982T1 (el) 2023-01-05
EP2833908A1 (en) 2015-02-11
PL2833908T3 (pl) 2022-03-21
RU2014140107A (ru) 2016-05-27
US11141472B2 (en) 2021-10-12
US20170209560A1 (en) 2017-07-27
EP4039271A1 (en) 2022-08-10
AU2013243535A1 (en) 2014-10-09
UA114502C2 (uk) 2017-06-26
CA2869603A1 (en) 2013-10-10
US20190134176A1 (en) 2019-05-09
RS62881B1 (sr) 2022-03-31
BR112014024533B1 (pt) 2021-06-01
MY166792A (en) 2018-07-23
US20130266601A1 (en) 2013-10-10
MX336504B (es) 2016-01-21
AR090611A1 (es) 2014-11-26
CN104271154B (zh) 2018-09-04
ES2905302T3 (es) 2022-04-07
US20150284677A1 (en) 2015-10-08
BR112014024533A2 (pt) 2017-08-08
HRP20220175T1 (hr) 2022-04-29
CL2014002674A1 (es) 2014-12-12
PH12014502250B1 (en) 2014-12-15
CO7160026A2 (es) 2015-01-15
AU2013243535C1 (en) 2018-03-01
JP2015512448A (ja) 2015-04-27
LT2833908T (lt) 2022-02-25
GT201400210A (es) 2015-06-02
JP6271502B2 (ja) 2018-01-31
HUE058321T2 (hu) 2022-07-28
CN104271154A (zh) 2015-01-07
KR101747507B1 (ko) 2017-06-14
MX2014012014A (es) 2014-11-10
NI201400117A (es) 2015-03-05
CR20140436A (es) 2014-11-12
HK1207284A1 (en) 2016-01-29
US20200330577A1 (en) 2020-10-22
MX354756B (es) 2018-03-20
TWI602575B (zh) 2017-10-21
SI2833908T1 (sl) 2022-04-29
TW201345550A (zh) 2013-11-16
CA2869603C (en) 2018-06-12
KR20150003257A (ko) 2015-01-08
AU2013243535B2 (en) 2017-10-19
PT2833908T (pt) 2022-02-17

Similar Documents

Publication Publication Date Title
PH12014502250A1 (en) Mycoplasma hyopneumoniae vaccine
MY199179A (en) Pvc/mycoplasma hyopneumonieau combination vaccine
PH12014502252A1 (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
NZ710744A (en) Methods for increasing immunoglobulin a levels
MX357061B (es) Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
IN2015DN03026A (https=)
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
PL2569007T3 (pl) Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
BR112015020053B8 (pt) Composições para cuidado oral
MX2013010618A (es) Metodo para preparar conjugados glucïdicos de glicopeptidos antigenicos multiples.